Just reported
From Regeneron Pharmaceuticals's results release of 30 अक्टूबर 2026; its quarterly report has since been filed.
Actual
$5.12B
+36% y/y
+19% q/q
Guided
—
No guide given
Actual
$18.45
+35% y/y
+51% q/q
Guided
—
No guide given
Actual
$2.05B
+99% y/y
+58% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
आमदनी के हिस्से quarter ended March 31, 2026 के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।
Dupixent
An injected medicine used for several allergic and inflammatory conditions, including eczema, asthma, and chronic obstructive pulmonary disease.
EYLEA HD
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
EYLEA
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
Libtayo
An immune-system cancer medicine used for several cancers, including certain skin cancers and lung cancer.
Praluent
An injected medicine that lowers cholesterol and reduces cardiovascular risk in some patients.
Otarmeni
A gene therapy for hearing loss caused by changes in the otoferlin gene.
Regeneron discovers, develops, makes, and sells medicines for conditions including eye diseases, allergic and inflammatory diseases, and cancer. Its medicines include Dupixent for inflammatory diseases, EYLEA for retinal conditions, and Libtayo for cancer. It sells some medicines itself and shares sales profits with partners such as Sanofi and Bayer, which also sell certain medicines.
Regeneron Pharmaceuticals, Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।
$955.80+0.4%13 नव॰ बंद भाव
30 सितंबर 2026 तक के आँकड़े, 30 अक्टूबर 2026 को दाखिल 10-Q से
Regeneron develops prescription medicines, led by Dupixent for allergic and inflammatory diseases, and sells them to drug distributors, pharmacies, hospitals, and health agencies.
The themes Regeneron Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade C+
भाव के नीचे की पट्टी हर तारीख की ग्रेड दिखाती है, जो सिर्फ़ उस समय तक सार्वजनिक दस्तावेज़ों से बनी है।
Regeneron Pharmaceuticals, Inc. के ग्रेड इतिहास की 41 तिमाहियों में से 2 दिखाई जा रही हैं। बाकी 39 नवंबर 2016 तक जाती हैं।
